Edesa Biotech Reports Fiscal Year 2021 Results : vimarsana.c

TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial

Related Keywords

California , United States , United Kingdom , Canada , Toronto , Ontario , British , Canadian , Hc Wainwright Bioconnect , Kathi Niffenegger , Gary Koppenjan , Linkedin , Edesa Biotech Inc , Twitter , Nasdaq , Exchange Commission , Strategic Innovation Fund , British Columbia Securities Commission , Securities Exchange , Edesa Biotech , Par Nijhawan , Chief Executive Officer , Chief Financial Officer Kathi Niffenegger , Fiscal Year Ended September , Strategic Innovation , Annual Lifesci Partners Corporate Access Event , Bioconnect Conference , Acute Respiratory Distress Syndrome , Securities Act , Securities Exchange Act , British Columbia Securities , Sedesa , Biotech , Reports , Iscal , Ear , 021 , Results ,